Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
前进保险前进保险(US:PGR) Businesswire·2026-02-08 04:40

公司动态 - 罗氏集团成员基因泰克宣布其研究性布鲁顿酪氨酸激酶抑制剂fenebrutinib在针对原发性进展型多发性硬化症患者的III期FENtrepid研究中达到主要终点 [1] - 数据显示fenebrutinib在减少残疾进展方面与Ocrevus相比达到了非劣效性 [1] - Fenebrutinib显示出将残疾进展风险降低12% [1]

Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) - Reportify